The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging.
Read More…
Industry, Sector and Symbol
Industry Chemicals & allied products
Sub-IndustryN/A
SectorBasic Materials
Phone302-773-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$6.64 billion
Profitability
Miscellaneous
Employees7,000
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Chemours (NYSE:CC) Frequently Asked Questions
What is Chemours' stock symbol?
Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."
How often does Chemours pay dividends? What is the dividend yield for Chemours?
Chemours declared a quarterly dividend on Wednesday, July 31st. Shareholders of record on Friday, August 16th will be paid a dividend of $0.25 per share on Monday, September 16th. This represents a $1.00 dividend on an annualized basis and a yield of 6.74%. The ex-dividend date of this dividend is Thursday, August 15th. View Chemours' Dividend History.
How will Chemours' stock buyback program work?
Chemours announced that its Board of Directors has initiated a stock buyback program on Monday, December 4th 2017, which allows the company to buyback $500,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company's management believes its stock is undervalued.
How were Chemours' earnings last quarter?
Chemours Co (NYSE:CC) issued its quarterly earnings data on Thursday, August, 1st. The specialty chemicals company reported $0.72 EPS for the quarter, missing the Zacks' consensus estimate of $0.90 by $0.18. The specialty chemicals company earned $1.41 billion during the quarter, compared to analysts' expectations of $1.53 billion. Chemours had a return on equity of 71.90% and a net margin of 10.33%. The business's revenue for the quarter was down 22.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.71 EPS. View Chemours' Earnings History.
When is Chemours' next earnings date?
What guidance has Chemours issued on next quarter's earnings?
Chemours issued an update on its FY19 earnings guidance on Thursday, August, 1st. The company provided EPS guidance of $2.37-3.08 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.88.
What price target have analysts set for CC?
12 analysts have issued 1-year target prices for Chemours' shares. Their forecasts range from $14.50 to $52.00. On average, they expect Chemours' stock price to reach $29.77 in the next year. This suggests a possible upside of 100.6% from the stock's current price. View Analyst Price Targets for Chemours.
What is the consensus analysts' recommendation for Chemours?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemours in the last year. There are currently 7 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Chemours.
Has Chemours been receiving favorable news coverage?
Headlines about CC stock have been trending negative recently, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Chemours earned a coverage optimism score of -2.6 on InfoTrie's scale. They also gave press coverage about the specialty chemicals company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Chemours.
Are investors shorting Chemours?
Chemours saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 12,560,000 shares, an increase of 14.5% from the August 30th total of 10,970,000 shares. Based on an average daily trading volume, of 3,460,000 shares, the short-interest ratio is currently 3.6 days. Approximately 7.8% of the shares of the company are short sold. View Chemours' Current Options Chain.
Who are some of Chemours' key competitors?
Some companies that are related to Chemours include Johnson Matthey (JMPLY), Huntsman (HUN), Ashland Global (ASH), W. R. Grace & Co (GRA), KURARAY CO LTD/ADR (KURRY), Univar (UNVR), Ingevity (NGVT), Balchem (BCPC), Olin (OLN), Innospec (IOSP), PQ Group (PQG), GCP Applied Technologies (GCP), Livent (LTHM), Innophos (IPHS) and Hawkins (HWKN).
What other stocks do shareholders of Chemours own?
Who are Chemours' key executives?
Chemours' management team includes the folowing people:
- Mr. Mark P. Vergnano, Pres, CEO & Director (Age 61)
- Mr. Mark E. Newman, Sr. VP & CFO (Age 56)
- Mr. David C. Shelton Esq., Sr. VP, Gen. Counsel & Corp. Sec. (Age 55)
- Mr. E. Bryan Snell, Pres of Titanium Technologies (Age 62)
- Mr. Paul Kirsch, Pres of Fluoroproducts Bus. (Age 55)
Who are Chemours' major shareholders?
Chemours' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Selz Capital LLC (0.34%), AI Financial Services LLC (0.06%), Pacer Advisors Inc. (0.04%), State of Alaska Department of Revenue (0.02%), Lau Associates LLC (0.02%) and Rothschild Investment Corp IL (0.01%). Company insiders that own Chemours stock include Amy Trojanowski, Bradley J Bell, Christian W Siemer, David C Shelton, E Bryan Snell, Erich Parker, Mark Newman, Mark P Vergnano, Mary B Cranston, Paul Kirsch, Richard H Brown and Susan M Kelliher. View Institutional Ownership Trends for Chemours.
Which major investors are selling Chemours stock?
CC stock was sold by a variety of institutional investors in the last quarter, including Selz Capital LLC and Lau Associates LLC. Company insiders that have sold Chemours company stock in the last year include Amy Trojanowski, Mark Newman and Paul Kirsch. View Insider Buying and Selling for Chemours.
Which major investors are buying Chemours stock?
CC stock was bought by a variety of institutional investors in the last quarter, including Pacer Advisors Inc., AI Financial Services LLC, Rothschild Investment Corp IL, State of Alaska Department of Revenue, Cerebellum GP LLC and Cerebellum GP LLC. Company insiders that have bought Chemours stock in the last two years include Bradley J Bell, David C Shelton, E Bryan Snell, Mark Newman, Mark P Vergnano, Mary B Cranston, Richard H Brown and Susan M Kelliher. View Insider Buying and Selling for Chemours.
How do I buy shares of Chemours?
Shares of CC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Chemours' stock price today?
One share of CC stock can currently be purchased for approximately $14.84.
How big of a company is Chemours?
Chemours has a market capitalization of $2.43 billion and generates $6.64 billion in revenue each year. The specialty chemicals company earns $995 million in net income (profit) each year or $5.67 on an earnings per share basis. Chemours employs 7,000 workers across the globe.View Additional Information About Chemours.
What is Chemours' official website?
How can I contact Chemours?
Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19899. The specialty chemicals company can be reached via phone at 302-773-1000 or via email at [email protected]
MarketBeat Community Rating for Chemours (NYSE CC)
MarketBeat's community ratings are surveys of what our community members think about Chemours and other stocks. Vote "Outperform" if you believe CC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CC will underperform the S&P 500 over the long term. You may vote once every thirty days.
